Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àڱ󻸷Áõ ȯÀÚÀÇ º¹°­ ¾×³» IL-6¿Í TNF-alphaÀÇ º¯È­ ¾ç»ó¿¡ °üÇÑ ¿¬±¸ A Study of Altered IL-6 and TNF-alpha Expression in Peritoneal Fluid of Patients with Endometriosis

´ëÇѺÒÀÓÇÐȸÁö 2006³â 33±Ç 1È£ p.45 ~ 52
°­Á¤¹è, ÀÌ¿µ°æ,
¼Ò¼Ó »ó¼¼Á¤º¸
°­Á¤¹è ( Kang Jeong-Bae ) 
ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

ÀÌ¿µ°æ ( Lee Young-Keong ) 
ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ »êºÎÀΰúÇб³½Ç

Abstract

¸ñ Àû: Àڱ󻸷Áõ°ú ÀÌ·Î ÀÎÇÑ ºÒÀÓÀÇ ¿øÀÎÀÎ ¸é¿ªÇÐÀû ÀÎÀÚ Áß ¼¼Æ÷-¸Å°³¼º ¸é¿ª°èÀÇ º¯È­¾ç»óÀ» ±Ô¸íÇϱâ À§ÇÏ¿© Àڱ󻸷Áõ ȯÀÚ¿Í Àڱ󻸷ÁõÀÌ ¾ø´Â ȯÀÚÀÇ º¹°­ ¾×À» äÃëÇÏ¿© ¸é¿ª¼¼Æ÷ÀÇ ºÐÆ÷¾ç»óÀ» ºñ±³ ºÐ¼®ÇÏ°íÀÚ IL-6¿Í TNF-¥á¸¦ ÃøÁ¤ÇÏ¿´´Ù. ¿¬±¸¹æ¹ý: Àڱ󻸷ÁõÀ¸·Î À°¾ÈÀû ¶Ç´Â Á¶Á÷°Ë»ç·Î È®ÁøµÈ ȯÀÚ ¶Ç´Â ºÒÀӰ˻縦 À§ÇØ Áø´ÜÀû º¹°­°æÀ» ½ÃÇàÇÑ 34¸íÀ» ¿¬±¸±ºÀ¸·Î µî·ÏÇÏ¿´À¸¸ç º» ¿¬±¸ ÀÌÀü¿¡ Àڱ󻸷Áõ°ú °ü·ÃµÈ ¾î¶°ÇÑ Ä¡·áµµ ¹ÞÀº ÀûÀÌ ¾ø°Å³ª º¹°­°æ ½Ã¼úÀ̳ª °³º¹¼ö¼ú°úÁ¤¿¡¼­ Àڱ󻸷Áõ ¼Ò°ß°ú Áõ»óÀÌ ¾ø´Â ȯÀÚ 37¸íÀ» ´ëÁ¶±ºÀ¸·Î ÇÏ¿´´Ù. µÎ ±ºÀÇ º¹°­ ¾×À» ÃßÃâÇÑ ´ÙÀ½ 30ºÐ À̳»¿¡ 400 g ¡¿ 10ºÐ µ¿¾È ¿ø½ÉºÐ¸® ÈÄ »óÃþ¾×¸¸ °Ë»ç¿ë±â¿¡ ¸ð¾Æ ¹ÐºÀÇÑ ÈÄ -70¡É ³Ãµ¿½Ç¿¡ º¸°üÇÏ¿© IL-6¿Í TNF-¥áÀÇ ³óµµ¸¦ "sandwich" enzyme-linked immunosorbent assays (ELISA: R & D Systems, Minnepolis, MN)·Î ÃøÁ¤ÇÏ¿´´Ù. °á °ú: 1. º¹°­ ¾×ÀÇ IL-6ÀÇ ³óµµ´Â Àڱ󻸷ÁõÀ¸·Î È®ÁøµÈ ¿¬±¸±º¿¡¼­´Â 38.9¡¾19.7 pg/mlÀ¸·Î ´ëÁ¶±ºÀÇ 22.4¡¾10.2 pg/mlº¸´Ù À¯ÀÇÇÏ°Ô Áõ°¡ÇÏ¿´°í (p=0.02), TNF-¥áÀÇ ³óµµµµ Àڱ󻸷ÁõÀÌ ÀÖ´Â ¿©¼º¿¡¼­ 20.6¡¾8.6 pg/ml·Î ´ëÁ¶±ºÀÇ 6.2¡¾3.5 pg/mlº¸´Ù À¯ÀÇÇÏ°Ô Áõ°¡ÇÏ¿´´Ù (p=0.01). 2.Àڱ󻸷Áõ¿©¼ºÀÇ »ý¸®Áֱ⺰ ³óµµ¿¡¼­ IL-6Àº Áõ½Ä±âº¸´Ù ºÐºñ±â¿¡ À¯ÀÇÇÏ°Ô Áõ°¡ÇÑ ¹Ý¸é (p=0.01), TNF-¥á´Â Â÷ÀÌ°¡ ¾ø¾ú´Ù (p>0.05). 3. IL-6Àº °¡ÀÓ¿©¼ºº¸´Ù ºÒÀÓ¿©¼º¿¡¼­ À¯ÀÇÇÏ°Ô Áõ°¡ ÇÏ¿´°í (p=0.03), TNF-¥á´Â µÎ ±º °£¿¡ À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù (p>0.05). 4. IL-6°ú TNF-¥á ¸ðµÎ ´ëÁ¶±º°ú Àڱ󻸷Áõ º´±â I°ú II´Â Åë°èÇÐÀûÀÎ À¯ÀǼºÀº ¾ø¾úÀ¸³ª º´±â III°ú IV´Â À¯ÀÇÇÏ°Ô Áõ°¡ÇÏ¿´´Ù (p<0.05). °á ·Ð: Àڱ󻸷ÁõÀΠȯÀÚÀÇ º¹°­ ¾×¿¡¼­ IL-6¿Í TNF-¥á°¡ Áõ°¡ÇÏ¿© Àڱ󻸷ÁõÀÇ »ý¼º°ú À¯Áö, Áõ»ó¹ßÇö¿¡ °ü¿©ÇÏ¸ç ºÒÀÓÀÇ À¯¹ß ¿äÀÎÀ¸·Î ¿©°ÜÁö³ª ÇâÈÄ ¸¹Àº ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸¿Í Àڱ󻸷Áõ°ú °¢Á¾ cytokine°úÀÇ »óÈ£ ¿¬°ü°ü°è¿¡ ´ëÇÑ ¿¬±¸°¡ ´õ ¸¹ÀÌ ÇÊ¿äÇϸ®¶ó »ç·áµÈ´Ù.

Objective: Our purpose was to investigate the relationship between the levels of IL-6 and tumor necrosis factor-¥á in the peritoneal fluid of women with and without endometriosis and infertile women. Methods: This study is prospective and case-control study in University hospital, enrolled thirty-four women with laparoscopic findings of minimal to severe endometriosis, and thirty-seven women with no visual evidence of pelvic endometriosis and with benign gynecologic disease. IL-6 and tumor necrosis factor-¥á levels in peritoneal fluid were determined using commercial ELISA. IL-6 and tumor necrosis factor-¥á concentrations were compared among women with and without endometriosis, and with infertile and fertile women, and then also compared according the revised American Fertility Society classification. Results: IL-6 and tumor necrosis factor-¥á concentrations were higher than in the peritoneal fluid of women with endometriosis than in matched normal controls. Cyclic variations in IL-6 concentrations were seen in peritoneal fluid from patients with endometriosis: the concentrations in the secretory phase were significantly higher than those in the proliferative phase. The concentrations were higher than among of infertile women than in fertile women. A significant correlation between IL-6 and tumor necrosis factor-¥á concentrations and endometriosis stage III and IV was noted. Conclusion: Increased levels of IL-6 and tumor necrosis factor-¥á in patients with endometriosis in the peritoneal fluid may be relate to the pathogenesis of endometriosis suggesting that partially contribute to the disturbed immune regulation observed in patients with endometriosis.

Å°¿öµå

Endometriosis;Interleukin-6;Tumor necrosis factor-alpha

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS